Comparing efficacy of Mustaghan vati and Pioglitazone in NAFLD

Evaluation of comparative efficacy of Mustaghan vati versus Pioglitazone in Non- Alcoholic Fatty Liver Disease- A Randomised Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087203

Enrollment

Registered

2025-05-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients not consuming any quantity of Alcohol for last 1 year. 2. Recently diagnosed patient having NAFLD with liver Fat content more than 0.64. 3. Male or female patient, of any race of age group 25 yrs to 55 yrs.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes mellitus, heart disease (ischemic or congestive), Hepatic disease, renal disease, any severe systemic co-morbidities. 2. Using any medication during the past 3 months, previous treatment (with thiazolidinediones, biguanides, or insulin) 3. Pregnant or lactating women 4. Patients who are immune-compromised.

Design outcomes

Primary

Measure	Time frame
Ayurvedic formulation Mustaghan vati prepared by Cyperus rotundus Linn. will be more effective than Tab. Pioglitazone in patients of NAFLD.Timepoint: 90 days.	—

Secondary

Measure	Time frame
Reduction in ALT and ASTTimepoint: 90 days	—

Countries

India

Contacts

Public ContactRohit A Waskar

Mahatma Gandhi Ayurved College Hospital and Research Centre, DMIHER

ayurrulz@gmail.com9404337799

Outcome results